MedTrace Logo

Multimorbidity and Sarcopenia Feasibility Study in Chronic Kidney Disease

NCT06109662 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2025-09-05

No results posted yet for this study

Summary

The aim of this research study is to look at the body composition (such as muscle and fat) in people with chronic kidney disease (CKD) and comparing it with body composition is people without CKD. The investigators currently understand loss of muscle function and mass (sarcopenia) affect the general health of people as they age, but this process seems to be more common, accelerated, and occurs earlier in people with CKD. There is limited evidence in this area, and we believe that if we understand when and how sarcopenia affects people with CKD, investigators can guide future trials and treatments to help treat sarcopenia, and in turn improve quality of life and health outcomes in people with CKD.

Conditions

Interventions

DIAGNOSTIC_TEST

Cystatin C eGFR

Cystatin C eGFR is not used routinely currently in clinical practice in the UK. It involved a blood test to analyse Cystatin C.

OTHER

Bioimpedance Analysis (Body composition analysis)

Participants will stand on a bioimpedance analysis machine which will measure different components of body composition

Sponsors & Collaborators

  • University Hospitals of Derby and Burton NHS Foundation Trust

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-02-12
Primary Completion
2025-11-02
Completion
2025-11-02

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06109662 on ClinicalTrials.gov